Aclaris Therapeutics (ACRS) Revenue (2017 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Revenue of $2.0 million for Q1 2026, up 37.18% year-over-year from $1.5 million in Q1 2025, and up 54.13% quarter-over-quarter from $1.3 million in Q4 2025.
Aclaris Therapeutics (ACRS) Revenue (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' Revenue history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.
- In Q1 2026, Revenue rose 37.18% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $8.4 million (down 52.94% YoY), while the FY2025 annual figure was $7.8 million, down 58.19% from the prior year.
- Revenue for Q1 2026 stood at $2.0 million, up from $1.3 million in the prior quarter.
- The five-year high for Revenue was $19.0 million in Q3 2022, with the low at $1.3 million in Q4 2025.
- The 5-year median for Revenue is $2.5 million (2023), against an average of $5.3 million.
- The sharpest annual moves came in 2022 and 2025: Revenue surged 1046.35% in 2022, then sank 85.94% in 2025.
- Aclaris Therapeutics' Revenue stood at $7.8 million in 2022, then jumped by 126.62% to $17.6 million in 2023, then plunged by 47.58% to $9.2 million in 2024, then tumbled by 85.94% to $1.3 million in 2025, then soared by 54.13% to $2.0 million in 2026.
- Business Quant data shows ACRS's Revenue at $2.0 million in Q1 2026, $1.3 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.63 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 1.78 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 9.21 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 17.57 Mn |
| Sep 30, 2023 | 9.28 Mn |
| Jun 30, 2023 | 1.87 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Dec 31, 2022 | 7.75 Mn |
| Sep 30, 2022 | 19.02 Mn |
| Jun 30, 2022 | 1.53 Mn |
| Mar 31, 2022 | 1.45 Mn |
| Dec 31, 2021 | 1.50 Mn |
| Sep 30, 2021 | 1.66 Mn |